# Marvell Technology, Inc.: financial statements, quarterly MRVL · Nasdaq · CIK 1835632 · [Technology](/sectors/technology.md) · fiscal year ends Jan 30 Pages: [Overview](/companies/mrvl.md) · [Financials](/companies/mrvl/financials.md) · [Filings](/companies/mrvl/filings.md) · [Insiders](/companies/mrvl/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mrvl/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2024 (2023-10-28) | Q4 FY2024 (2024-02-03) | Q1 FY2025 (2024-05-04) | Q2 FY2025 (2024-08-03) | Q3 FY2025 (2024-11-02) | Q4 FY2025 (2025-02-01) | Q1 FY2026 (2025-05-03) | Q2 FY2026 (2025-08-02) | Q3 FY2026 (2025-11-01) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-05-02) | Q2 FY2027 (2026-08-01) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,419](/filings/0001835632-24-000200.md) | [1,427 d](/filings/0001835632-26-000011.md) | [1,161](/filings/0001835632-25-000117.md) | [1,273](/filings/0001835632-25-000189.md) | [1,516](/filings/0001835632-25-000197.md) | [1,817 d](/filings/0001835632-26-000011.md) | [1,895](/filings/0001835632-26-000019.md) | [2,006](/filings/0001835632-26-000025.md) | [2,075](/filings/0001835632-25-000197.md) | [2,219 d](/filings/0001835632-26-000011.md) | [2,418](/filings/0001835632-26-000019.md) | [2,739](/filings/0001835632-26-000025.md) | | Cost of revenue | $m | [867](/filings/0001835632-24-000200.md) | [762 d](/filings/0001835632-26-000011.md) | [633](/filings/0001835632-25-000117.md) | [685](/filings/0001835632-25-000189.md) | [1,167](/filings/0001835632-25-000197.md) | [900 d](/filings/0001835632-26-000011.md) | [943](/filings/0001835632-26-000019.md) | [996](/filings/0001835632-26-000025.md) | [1,005](/filings/0001835632-25-000197.md) | [1,071 d](/filings/0001835632-26-000011.md) | [1,157](/filings/0001835632-26-000019.md) | [1,284](/filings/0001835632-26-000025.md) | | Gross profit | $m | [551](/filings/0001835632-24-000200.md) | [664 d](/filings/0001835632-26-000011.md) | [528](/filings/0001835632-25-000117.md) | [588](/filings/0001835632-25-000189.md) | [349](/filings/0001835632-25-000197.md) | [917 d](/filings/0001835632-26-000011.md) | [952](/filings/0001835632-26-000019.md) | [1,011](/filings/0001835632-26-000025.md) | [1,070](/filings/0001835632-25-000197.md) | [1,148 d](/filings/0001835632-26-000011.md) | [1,261](/filings/0001835632-26-000019.md) | [1,456](/filings/0001835632-26-000025.md) | | Research and development | $m | [481](/filings/0001835632-24-000200.md) | [460 d](/filings/0001835632-26-000011.md) | [476](/filings/0001835632-25-000117.md) | [487](/filings/0001835632-25-000189.md) | [489](/filings/0001835632-25-000197.md) | [499 d](/filings/0001835632-26-000011.md) | [508](/filings/0001835632-26-000019.md) | [519](/filings/0001835632-26-000025.md) | [513](/filings/0001835632-25-000197.md) | [536 d](/filings/0001835632-26-000011.md) | [652](/filings/0001835632-26-000019.md) | [741](/filings/0001835632-26-000025.md) | | Selling, general and administrative | $m | [213](/filings/0001835632-24-000200.md) | [212 d](/filings/0001835632-26-000011.md) | [200](/filings/0001835632-25-000117.md) | [197](/filings/0001835632-25-000189.md) | [205](/filings/0001835632-25-000197.md) | [196 d](/filings/0001835632-26-000011.md) | [186](/filings/0001835632-26-000019.md) | [193](/filings/0001835632-26-000025.md) | [190](/filings/0001835632-25-000197.md) | [198 d](/filings/0001835632-26-000011.md) | [258](/filings/0001835632-26-000019.md) | [258](/filings/0001835632-26-000025.md) | | Operating income | $m | [(146)](/filings/0001835632-24-000200.md) | [(33.3) d](/filings/0001835632-26-000011.md) | [(152)](/filings/0001835632-25-000117.md) | [(100)](/filings/0001835632-25-000189.md) | [(703)](/filings/0001835632-25-000197.md) | [235 d](/filings/0001835632-26-000011.md) | [271](/filings/0001835632-26-000019.md) | [290](/filings/0001835632-26-000025.md) | [358](/filings/0001835632-25-000197.md) | [404 d](/filings/0001835632-26-000011.md) | [339](/filings/0001835632-26-000019.md) | [460](/filings/0001835632-26-000025.md) | | Interest expense | $m | [52.6](/filings/0001835632-23-000046.md) | [52.6 d](/filings/0001835632-24-000009.md) | [48.8](/filings/0001835632-24-000063.md) | [48.4](/filings/0001835632-25-000189.md) | [47.2](/filings/0001835632-25-000197.md) | [45.0 d](/filings/0001835632-26-000011.md) | [48.7](/filings/0001835632-26-000019.md) | [51.9](/filings/0001835632-26-000025.md) | [51.2](/filings/0001835632-25-000197.md) | [50.8 d](/filings/0001835632-26-000011.md) | [52.8](/filings/0001835632-26-000019.md) | [61.6](/filings/0001835632-26-000025.md) | | Income tax | $m | [(23.2)](/filings/0001835632-24-000200.md) | [305 d](/filings/0001835632-26-000011.md) | [17.8](/filings/0001835632-25-000117.md) | [47.1](/filings/0001835632-25-000189.md) | [(74.2)](/filings/0001835632-25-000197.md) | [(0.4) d](/filings/0001835632-26-000011.md) | [38.0](/filings/0001835632-26-000019.md) | [38.9](/filings/0001835632-26-000025.md) | [314](/filings/0001835632-25-000197.md) | [(14.5) d](/filings/0001835632-26-000011.md) | [48.8](/filings/0001835632-26-000019.md) | [70.3](/filings/0001835632-26-000025.md) | | Net income | $m | [(164)](/filings/0001835632-24-000200.md) | [(393) d](/filings/0001835632-26-000011.md) | [(216)](/filings/0001835632-25-000197.md) | [(193)](/filings/0001835632-25-000197.md) | [(676)](/filings/0001835632-25-000197.md) | [200 d](/filings/0001835632-26-000011.md) | [178](/filings/0001835632-26-000025.md) | [195](/filings/0001835632-26-000025.md) | [1,901](/filings/0001835632-25-000197.md) | [396 d](/filings/0001835632-26-000011.md) | [34.5](/filings/0001835632-26-000025.md) | [308](/filings/0001835632-26-000025.md) | | Diluted EPS | $ per share | [(0.19)](/filings/0001835632-24-000200.md) | not reported | [(0.25)](/filings/0001835632-25-000117.md) | [(0.22)](/filings/0001835632-25-000189.md) | [(0.78)](/filings/0001835632-25-000197.md) | not reported | [0.20](/filings/0001835632-26-000019.md) | [0.22](/filings/0001835632-26-000025.md) | [2.20](/filings/0001835632-25-000197.md) | not reported | [0.04](/filings/0001835632-26-000019.md) | [0.33](/filings/0001835632-26-000025.md) | | Basic EPS | $ per share | [(0.19)](/filings/0001835632-24-000200.md) | not reported | [(0.25)](/filings/0001835632-25-000117.md) | [(0.22)](/filings/0001835632-25-000189.md) | [(0.78)](/filings/0001835632-25-000197.md) | not reported | [0.21](/filings/0001835632-26-000019.md) | [0.23](/filings/0001835632-26-000025.md) | [2.22](/filings/0001835632-25-000197.md) | not reported | [0.04](/filings/0001835632-26-000019.md) | [0.34](/filings/0001835632-26-000025.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2024 (2023-10-28) | FY2024 (2024-02-03) | Q1 FY2025 (2024-05-04) | Q2 FY2025 (2024-08-03) | Q3 FY2025 (2024-11-02) | FY2025 (2025-02-01) | Q1 FY2026 (2025-05-03) | Q2 FY2026 (2025-08-02) | Q3 FY2026 (2025-11-01) | FY2026 (2026-01-31) | Q1 FY2027 (2026-05-02) | Q2 FY2027 (2026-08-01) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.7](/filings/0001835632-23-000046.md) | [1.0](/filings/0001835632-25-000057.md) | [0.8](/filings/0001835632-24-000063.md) | [0.8](/filings/0001835632-24-000142.md) | [0.9](/filings/0001835632-24-000200.md) | [0.9](/filings/0001835632-26-000011.md) | [0.9](/filings/0001835632-25-000117.md) | [1.2](/filings/0001835632-25-000189.md) | [2.7](/filings/0001835632-25-000197.md) | [2.6](/filings/0001835632-26-000025.md) | [3.8](/filings/0001835632-26-000019.md) | [3.9](/filings/0001835632-26-000025.md) | | Current assets | $bn | [3.0](/filings/0001835632-23-000046.md) | [3.1](/filings/0001835632-25-000057.md) | [2.6](/filings/0001835632-24-000063.md) | [2.8](/filings/0001835632-24-000142.md) | [2.8](/filings/0001835632-24-000200.md) | [3.1](/filings/0001835632-26-000011.md) | [3.8](/filings/0001835632-25-000117.md) | [4.5](/filings/0001835632-25-000189.md) | [5.5](/filings/0001835632-25-000197.md) | [6.5](/filings/0001835632-26-000025.md) | [7.5](/filings/0001835632-26-000019.md) | [7.9](/filings/0001835632-26-000025.md) | | Total assets | $bn | [21.7](/filings/0001835632-23-000046.md) | [21.2](/filings/0001835632-25-000057.md) | [20.5](/filings/0001835632-24-000063.md) | [20.3](/filings/0001835632-24-000142.md) | [19.7](/filings/0001835632-24-000200.md) | [20.2](/filings/0001835632-26-000011.md) | [20.0](/filings/0001835632-25-000117.md) | [20.6](/filings/0001835632-25-000189.md) | [21.6](/filings/0001835632-25-000197.md) | [22.3](/filings/0001835632-26-000025.md) | [26.9](/filings/0001835632-26-000019.md) | [27.6](/filings/0001835632-26-000025.md) | | Current liabilities | $bn | [1.9](/filings/0001835632-23-000046.md) | [1.8](/filings/0001835632-25-000057.md) | [1.5](/filings/0001835632-24-000063.md) | [1.5](/filings/0001835632-24-000142.md) | [1.8](/filings/0001835632-24-000200.md) | [2.0](/filings/0001835632-26-000011.md) | [2.9](/filings/0001835632-25-000117.md) | [2.4](/filings/0001835632-25-000189.md) | [2.7](/filings/0001835632-25-000197.md) | [3.2](/filings/0001835632-26-000025.md) | [2.3](/filings/0001835632-26-000019.md) | [2.5](/filings/0001835632-26-000025.md) | | Total liabilities | $bn | [6.5](/filings/0001835632-23-000046.md) | [6.4](/filings/0001835632-25-000057.md) | [6.0](/filings/0001835632-24-000063.md) | [6.1](/filings/0001835632-24-000142.md) | [6.3](/filings/0001835632-24-000200.md) | [6.8](/filings/0001835632-26-000011.md) | [6.7](/filings/0001835632-25-000117.md) | [7.2](/filings/0001835632-25-000189.md) | [7.5](/filings/0001835632-25-000197.md) | [8.0](/filings/0001835632-26-000025.md) | [8.7](/filings/0001835632-26-000019.md) | [9.0](/filings/0001835632-26-000025.md) | | Long-term debt | $bn | [4.1](/filings/0001835632-23-000046.md) | [4.1](/filings/0001835632-25-000057.md) | [4.0](/filings/0001835632-24-000063.md) | [4.0](/filings/0001835632-24-000142.md) | [4.0](/filings/0001835632-24-000200.md) | [3.9](/filings/0001835632-26-000011.md) | [3.0](/filings/0001835632-25-000117.md) | [4.0](/filings/0001835632-25-000189.md) | [4.0](/filings/0001835632-25-000197.md) | [4.0](/filings/0001835632-26-000025.md) | [5.0](/filings/0001835632-26-000019.md) | [5.0](/filings/0001835632-26-000025.md) | | Current portion of debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.5](/filings/0001835632-26-000025.md) | [0.0](/filings/0001835632-26-000019.md) | [0.0](/filings/0001835632-26-000025.md) | | Short-term borrowings | $bn | [0.1](/filings/0001835632-23-000046.md) | [0.1](/filings/0001835632-25-000057.md) | [0.1](/filings/0001835632-24-000063.md) | [0.1](/filings/0001835632-24-000142.md) | [0.1](/filings/0001835632-24-000200.md) | [0.1](/filings/0001835632-26-000011.md) | [1.3](/filings/0001835632-25-000117.md) | [0.5](/filings/0001835632-25-000189.md) | [0.5](/filings/0001835632-25-000197.md) | [0.5](/filings/0001835632-26-000025.md) | [0.0](/filings/0001835632-26-000019.md) | [0.0](/filings/0001835632-26-000025.md) | | Shareholders' equity | $bn | [15.2](/filings/0001835632-24-000200.md) | [14.8](/filings/0001835632-26-000011.md) | [14.5](/filings/0001835632-25-000197.md) | [14.2](/filings/0001835632-25-000197.md) | [13.4](/filings/0001835632-25-000197.md) | [13.4](/filings/0001835632-26-000025.md) | [13.3](/filings/0001835632-26-000025.md) | [13.4](/filings/0001835632-26-000025.md) | [14.1](/filings/0001835632-25-000197.md) | [14.3](/filings/0001835632-26-000025.md) | [18.2](/filings/0001835632-26-000025.md) | [18.5](/filings/0001835632-26-000025.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2024 (2023-10-28) | Q4 FY2024 (2024-02-03) | Q1 FY2025 (2024-05-04) | Q2 FY2025 (2024-08-03) | Q3 FY2025 (2024-11-02) | Q4 FY2025 (2025-02-01) | Q1 FY2026 (2025-05-03) | Q2 FY2026 (2025-08-02) | Q3 FY2026 (2025-11-01) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-05-02) | Q2 FY2027 (2026-08-01) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [503 d](/filings/0001835632-24-000200.md) | [547 d](/filings/0001835632-26-000011.md) | [325](/filings/0001835632-25-000117.md) | [306 d](/filings/0001835632-25-000189.md) | [536 d](/filings/0001835632-25-000197.md) | [514 d](/filings/0001835632-26-000011.md) | [333](/filings/0001835632-26-000019.md) | [462 d](/filings/0001835632-26-000025.md) | [582 d](/filings/0001835632-25-000197.md) | [374 d](/filings/0001835632-26-000011.md) | [639](/filings/0001835632-26-000019.md) | [606 d](/filings/0001835632-26-000025.md) | | Capital expenditure | $m | [54.4 d](/filings/0001835632-24-000200.md) | [71.0 d](/filings/0001835632-26-000011.md) | [91.5](/filings/0001835632-25-000117.md) | [48.2 d](/filings/0001835632-25-000189.md) | [75.0 d](/filings/0001835632-25-000197.md) | [69.9 d](/filings/0001835632-26-000011.md) | [119](/filings/0001835632-26-000019.md) | [47.5 d](/filings/0001835632-26-000025.md) | [73.5 d](/filings/0001835632-25-000197.md) | [114 d](/filings/0001835632-26-000011.md) | [156](/filings/0001835632-26-000019.md) | [127 d](/filings/0001835632-26-000025.md) | | Dividends paid | $m | [51.8 d](/filings/0001835632-24-000200.md) | [51.9 d](/filings/0001835632-26-000011.md) | [51.8](/filings/0001835632-25-000117.md) | [51.9 d](/filings/0001835632-25-000189.md) | [51.9 d](/filings/0001835632-25-000197.md) | [51.9 d](/filings/0001835632-26-000011.md) | [51.8](/filings/0001835632-26-000019.md) | [51.7 d](/filings/0001835632-26-000025.md) | [50.8 d](/filings/0001835632-25-000197.md) | [50.8 d](/filings/0001835632-26-000011.md) | [53.8](/filings/0001835632-26-000019.md) | [53.9 d](/filings/0001835632-26-000025.md) | | Share repurchases | $m | [50.0 d](/filings/0001835632-24-000200.md) | [100 d](/filings/0001835632-26-000011.md) | [150](/filings/0001835632-25-000117.md) | [175 d](/filings/0001835632-25-000189.md) | [200 d](/filings/0001835632-25-000197.md) | [200 d](/filings/0001835632-26-000011.md) | [340](/filings/0001835632-26-000019.md) | [200 d](/filings/0001835632-26-000025.md) | [1,300 d](/filings/0001835632-25-000197.md) | [200 d](/filings/0001835632-26-000011.md) | [200](/filings/0001835632-26-000019.md) | [200 d](/filings/0001835632-26-000025.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2023 (2022-10-29) | Q1 FY2024 (2023-04-29) | Q2 FY2024 (2023-07-29) | Q3 FY2024 (2023-10-28) | Q1 FY2025 (2024-05-04) | Q2 FY2025 (2024-08-03) | Q3 FY2025 (2024-11-02) | Q1 FY2026 (2025-05-03) | Q2 FY2026 (2025-08-02) | Q3 FY2026 (2025-11-01) | Q1 FY2027 (2026-05-02) | Q2 FY2027 (2026-08-01) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [858](/filings/0001835632-23-000046.md) | [857](/filings/0001835632-24-000063.md) | [861](/filings/0001835632-24-000142.md) | [863](/filings/0001835632-24-000200.md) | [865](/filings/0001835632-25-000117.md) | [866](/filings/0001835632-25-000189.md) | [866](/filings/0001835632-25-000197.md) | [876](/filings/0001835632-26-000019.md) | [870](/filings/0001835632-26-000025.md) | [864](/filings/0001835632-25-000197.md) | [893](/filings/0001835632-26-000019.md) | [921](/filings/0001835632-26-000025.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 876,900,000 at 2026-08-21, from the cover of the [10-Q filed 2026-08-28](/filings/0001835632-26-000025.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.